Cantargia has completed a club deal share issuance of approximately SEK 59 million. Investors represent a variety of Swedish and international investors including certain existing shareholders, notably the Fourth Swedish National Pension Fund (AP4), the First Swedish National Pension Fund (AP1) and Alecta Tjänstepension.

Cantargia is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Zonda Partners and Van Lanschot Kempen acted as Joint Global Coordinators and Joint Bookrunners, and Oppenheimer & Co acted as financial adviser. Baker McKenzie acted as legal adviser to the Joint Bookrunners with a capital markets team consisting of Joakim Falkner, Per Blom and Sophie Gidlund.

Explore Our Newsroom